Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD-mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. (Blood. 2000;96:3907-3914)

[1]  E. Vellenga,et al.  Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. , 2000, The Biochemical journal.

[2]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[3]  K.,et al.  Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells , 2000, British journal of haematology.

[4]  K. Horibe,et al.  Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. , 1999, Medical and pediatric oncology.

[5]  K. Ihara,et al.  High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. , 1999, Pediatric hematology and oncology.

[6]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[7]  A. Martens,et al.  Human acute myeloid leukemia cells with internal tandem duplications in the Flt3 gene show reduced proliferative ability in stroma supported long-term cultures , 1999, Leukemia.

[8]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[9]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[10]  H. Broxmeyer,et al.  Flt3 signaling involves tyrosyl‐phosphorylation of SHP‐2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells , 1999, Journal of leukocyte biology.

[11]  T. Kaisho,et al.  Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.

[12]  H. Broxmeyer,et al.  p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. , 1999, Biochemical and biophysical research communications.

[13]  M. Taniwaki,et al.  Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia , 1999, Leukemia.

[14]  A. Miyajima,et al.  Transcriptional regulation of the beta-casein gene by cytokines: cross-talk between STAT5 and other signaling molecules. , 1998, Molecular endocrinology.

[15]  H. Griesser,et al.  Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. , 1998, Blood.

[16]  H. Saito,et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product , 1998, Leukemia.

[17]  K. Götze,et al.  Flt3high and Flt3low CD34+Progenitor Cells Isolated From Human Bone Marrow Are Functionally Distinct , 1998 .

[18]  K. Götze,et al.  Flt 3 high and Flt 3 low CD 34 1 Progenitor Cells Isolated From Human Bone Marrow Are Functionally Distinct , 1998 .

[19]  C. Civin,et al.  Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. , 1998, Blood.

[20]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[21]  N. Miyasaka,et al.  Erythropoietin Induces Tyrosine Phosphorylation of the Interleukin-3 Receptor β Subunit (βIL3 ) and Recruitment of Stat5 to Possible Stat5-Docking Sites in βIL3 , 1997 .

[22]  N. Miyasaka,et al.  Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3. , 1997, Blood.

[23]  M. Minden,et al.  Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells. , 1997, Experimental hematology.

[24]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[25]  Z. Estrov,et al.  Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. , 1996, Blood.

[26]  S. Jacobsen,et al.  The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. , 1996, Journal of immunology.

[27]  D. Birnbaum,et al.  Phosphatidylinositol-3′ Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.

[28]  Y. Matsuzawa,et al.  Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. , 1996, Blood.

[29]  H. Drexler,et al.  Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. , 1996, Leukemia.

[30]  D. Hirschstein,et al.  Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. , 1996, Experimental hematology.

[31]  A. Ganser,et al.  Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells. , 1996, Experimental hematology.

[32]  D. Birnbaum,et al.  Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. , 1996, Leukemia.

[33]  M. Borowitz,et al.  Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. , 1996, Blood.

[34]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[35]  M. Brizzi,et al.  Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. , 1995, Blood.

[36]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.

[37]  M. Minden,et al.  c-KIT expression enhances the leukemogenic potential of 32D cells. , 1995, The Journal of clinical investigation.

[38]  A. Miyajima,et al.  Interleukin‐3, granulocyte‐macrophage colony stimulating factor and interleukin‐5 transduce signals through two STAT5 homologs. , 1995, The EMBO journal.

[39]  S. Lyman,et al.  Biology and potential clinical applications of flt3 ligand , 1995, Current opinion in hematology.

[40]  H. Mckenna,et al.  Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. , 1994, Blood.

[41]  T. Mcclanahan,et al.  Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs , 1994, Nature.

[42]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Farrah,et al.  Molecular cloning of a ligand for the flt3 flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells , 1993, Cell.

[44]  T. Bird,et al.  Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. , 1993, Oncogene.

[45]  D. Birnbaum,et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.

[46]  D. Pardoll,et al.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations , 1991, Cell.